Septerna, Inc. (SEPN) Stock
SEPN has an Alpha Score of 48 out of 100 (weak), computed on Oct 31, 2026 from 2 of 4 sub-scores. 5 of the hedge funds AlphaScala tracks reported SEPN in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Hussman Investment Trust's at $2.47M. Company insiders reported 0 open-market buys and 8 sales on SEC Form 4 in the 90 days to Nov 2, 2026.
What is SEPN's Alpha Score?
How it works →Alpha Score of 48 reflects weak overall profile with strong momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 31, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own SEPN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Hussman Investment Trust John Hussman | 63K | $2.47M | n/a |
| Millennium Management Israel Englander | 51K | $1.69M | -59% |
| D.E. Shaw David Shaw | 46K | $1.56M | NEW |
| Renaissance Technologies Jim Simons (founder) | 41K | $1.39M | +10% |
| Citadel Ken Griffin | 6K | $212.7K | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Septerna, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Bhatt Elizabeth | President and COO | SELL | 1.1K | $40K |
| Oct 15, 26 | Bhatt Elizabeth | President and COO | SELL | 2.9K | $109K |
| Sep 1, 26 | Long Daniel D. | SVP, Drug Discovery | SELL | 3.3K | $126K |
| Aug 12, 26 | Third Rock Ventures V, L.P. | 10%+ Owner | SELL | 147.1K | $7.4M |
| Aug 12, 26 | Third Rock Ventures V, L.P. | 10%+ Owner | SELL | 141 | $7K |
| Aug 12, 26 | Ra Capital Management, L.P. | Director | SELL | 746.5K | $31.7M |
| Aug 12, 26 | Ra Capital Management, L.P. | Director | SELL | 746.5K | $31.7M |
| Aug 11, 26 | Bhatt Elizabeth | President and COO | SELL | 25.0K | $1.1M |
| Aug 3, 26 | Long Daniel D. | SVP, Drug Discovery | SELL | 1.0K | $34K |
| Aug 3, 26 | Long Daniel D. | SVP, Drug Discovery | SELL | 2.3K | $81K |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →What are SEPN's key statistics?
Key statistics as of Oct 31, 2026
How does SEPN's valuation compare with the Healthcare sector?
| Metric | SEPN | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -24.51% | 4.85% | 143 |
| Return on equity | -6.31% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
SEPN price chart
Powered by TradingViewWhat does Septerna, Inc. do?
Septerna Inc. is a clinical-stage biotechnology company specializing in the discovery and development of oral small molecule therapies targeting G protein-coupled receptors (GPCRs). Powered by its proprietary Native Complex Platform, the company unlocks challenging GPCR targets to create novel medicines for patients with significant unmet needs. Its wholly-owned pipeline focuses on three key therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Notable programs include the PTH1R program with oral small molecule Parathyroid Hormone 1 Receptor agonists for hypoparathyroidism; SEP-631, an oral MRGPRX2 negative allosteric modulator for chronic spontaneous urticaria and mast cell-driven diseases; the TSHR program for Graves’ disease and thyroid eye disease; and oral single- and multi-incretin receptor agonists for metabolic disorders like obesity and type 2 diabetes. Septerna Inc. advances a deep portfolio of GPCR-targeted candidates, employing novel mechanistic approaches to address diseases across these fields. Founded in 2019 and headquartered in South San Francisco, California, the company drives innovation in GPCR drug discovery through its industrial-scale platform and expert team.